This week’s episode is part 2 of testicular cancer 2025 updates. We had the honor of interviewing Dr. Larry Einhorn a true legend when it comes to the management of non-seminoma last year, released 4/22/2024, but today, we will be repeating a quick overview of the staging and management for initial treatment of non-seminoma as well as refractory disease.

This week’s episode is part 1 of testicular cancer 2025 updates. We had the honor of interviewing Dr. Larry Einhorn a true legend when it comes to the management of testicular CA last year, released in April 2024, but today, we will be repeating a quick overview of risk factors and staging for testicular cancer, as well as the management of seminoma.

This week’s episode will be focusing on an update of CLL. We will go over  important details on the presentation, diagnosis, prognostic factors, and treatment options for initial and refractory disease, as well as key toxicities. 

We are so excited to welcome back Dr. Charles (Chuck) Ryan for our 2025 prostate cancer updates. Dr. Ryan is an internationally recognized GU oncologist and prostate cancer expert, seeing patients at MSK in NYC, and co-host of the podcast 'The Good News About Cancer'. 

This episode will cover metastatic prostate cancer including board review pearls & key toxicities of treatments, upcoming exciting research in PCa, and advice for trainees/early career faculty.

We are so excited to welcome Dr. Charles (Chuck) Ryan for our 2025 prostate cancer updates. Dr. Ryan is an internationally recognized GU oncologist and prostate cancer expert, seeing patients at Memorial Sloan Kettering in NYC. 

This episode will cover localized prostate cancer, risk factors, staging, role of PET PSMA, risk stratification, treatments, as well as introduce biochemical recurrence.

Today’s episode is focusing on what you need to know regarding metastatic colon cancer. This will include the need to know about molecular studies, treatment, and surgery for oligometastatic disease. There has been three breakthroughs since we last covered this topic in the treatment of metastatic CRC based on molecular findings that we will go over today.

Today’s episode is focusing on what you need to know regarding early stage colorectal cancer (CRC) as of 2025. The last time we covered this topic was in 2023 and things continue to change. We will go over all the important details on the diagnosis, presentation, diagnostic work-up, role of ctDNA, staging, treatment, and surveillance of localized CRC. 

We are so honored to welcome back Dr. S. Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, Minnesota. He is also Editor-In-Chief of Blood Cancer Journal and the Chairperson of the Board of the International Myeloma Foundation. This week’s episode will be focusing on additional pearls for the treatment of Multiple Myeloma including options for refractory disease, as well as advice for trainees.

Today we will be discussing a few of the exciting abstracts presented at ASCO GU (Feb 13-15 2025) for prostate CA (TALAPRO-2), bladder CA (EV-302, CM-274, NIAGARA), and RCC (COSMIC-313, KIM-1).

Today we will be discussing exciting data to come at ASCO GU (Feb 13-15 2025) in terms of research for prostate CA, bladder CA, RCC and other rarer GU tumors.